Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vanta BioscienceBOM:540729 -4.73%52 EV-to-FCF is -10.23 as of Aug. 09, 2026. GuruFocus rates BOM:540729 with a GF Score™ of 52/100 and a GF Value™ of ₹11.84 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 101 Medical Diagnostics & Research companies, Vanta Bioscience ranks worse than 990098.02% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vanta Bioscience's Enterprise Value is ₹534.11 Mil.
Vanta Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-52.19 Mil. Therefore, Vanta Bioscience's EV-to-FCF for today is -10.23.
The historical rank and industry rank for Vanta Bioscience's EV-to-FCF or its related term are showing as below:
BOM:540729'
s EV-to-FCF Range Over the Past 10 Years
Min: -147.13 Med: -9.58 Max: -2.33
Current: -10.23
During the past 10 years, the highest EV-to-FCF of Vanta Bioscience was -2.33. The lowest was -147.13. And the median was -9.58.
BOM:540729's EV-to-FCF is ranked worse than 100% of 101
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.68
vs BOM:540729: -10.23
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vanta Bioscience's PE Ratio (TTM) for today is calculated as:
Vanta Bioscience's share price for today is ₹21.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vanta Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vanta Bioscience EV-to-FCF Related Terms
Vanta Bioscience EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540729 vs TMO, DHR, IDXX: EV-to-FCF Comparison
For the Diagnostics & Research subindustry, Vanta Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's EV-to-FCF falls into.
Vanta Bioscience's current Enterprise Value is ₹534.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vanta Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-52.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanta Bioscience (BOM:540729) has a EV-to-FCF of -10.23 as of Aug. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vanta Bioscience and its competitors. According to the industry distribution chart, Vanta Bioscience ranks #999999 out of 101 companies in the Medical Diagnostics & Research industry.
Is Vanta Bioscience's EV-to-FCF too high?
Vanta Bioscience's current EV-to-FCF is -10.23. Based on the distribution chart, Vanta Bioscience ranks #999999 out of 101 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Vanta Bioscience has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vanta Bioscience ranks #999999 out of 101 companies for EV-to-FCF. This places Vanta Bioscience in the lower half of its industry. The industry median EV-to-FCF is 26.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.68, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vanta Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanta Bioscience's current EV-to-FCF is -10.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.84, compared to a current price of ₹21.75 — trading 83.7% above its estimated fair value. The current EV-to-FCF is -10.23. Vanta Bioscience's overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current EV-to-FCF is -10.23 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹21.75 is trading 83.7% above its estimated GF Value™ of ₹11.84.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
EV-to-FCF: -10.23
GF Value™: ₹11.84 vs. price of ₹21.75 (83.7% above fair value)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
52GF Score
Get the complete analysis for BOM:540729
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
